AU2002342715A1 - Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors - Google Patents

Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors

Info

Publication number
AU2002342715A1
AU2002342715A1 AU2002342715A AU2002342715A AU2002342715A1 AU 2002342715 A1 AU2002342715 A1 AU 2002342715A1 AU 2002342715 A AU2002342715 A AU 2002342715A AU 2002342715 A AU2002342715 A AU 2002342715A AU 2002342715 A1 AU2002342715 A1 AU 2002342715A1
Authority
AU
Australia
Prior art keywords
pain
prevention
stress
treatment
protein kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002342715A
Other languages
English (en)
Inventor
Lisa D. Aimone
Robert L. Hudkins
Mathew S. Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of AU2002342715A1 publication Critical patent/AU2002342715A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2002342715A 2001-05-16 2002-05-16 Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors Abandoned AU2002342715A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29122701P 2001-05-16 2001-05-16
US60/291,227 2001-05-16
US10/146,680 US7018999B2 (en) 2001-05-16 2002-05-15 Methods for the treatment and prevention of pain
US10/146,680 2002-05-15
PCT/US2002/015667 WO2002092065A2 (en) 2001-05-16 2002-05-16 Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors

Publications (1)

Publication Number Publication Date
AU2002342715A1 true AU2002342715A1 (en) 2002-11-25

Family

ID=26844179

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002342715A Abandoned AU2002342715A1 (en) 2001-05-16 2002-05-16 Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors

Country Status (13)

Country Link
US (1) US7018999B2 (de)
EP (1) EP1389100B1 (de)
JP (1) JP2004534751A (de)
AR (1) AR035971A1 (de)
AT (1) ATE410201T1 (de)
AU (1) AU2002342715A1 (de)
CA (1) CA2447091C (de)
DE (1) DE60229233D1 (de)
DK (1) DK1389100T3 (de)
ES (1) ES2314101T3 (de)
HK (1) HK1062806A1 (de)
MX (1) MXPA03010451A (de)
WO (1) WO2002092065A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241779B2 (en) 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
CN103965204B (zh) 2008-11-19 2016-09-07 赛福伦公司 吲唑并[5,4-a]吡咯并[3,4-c]咔唑化合物的新形式
WO2018175670A1 (en) 2017-03-22 2018-09-27 The Research Foundation For The State University Of New York Matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1381031A (en) * 1920-01-19 1921-06-07 Thompson James Dumping-wagon
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
JPH07505124A (ja) 1991-11-08 1995-06-08 ザ ユニバーシティ オブ サザン カリフォルニア ニューロトロフィン活性増強のためのｋ−２５２化合物を含む組成物
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
JP3344586B2 (ja) * 1993-05-28 2002-11-11 セファロン，インコーポレイテッド インドロカルバゾール誘導体を含有する前立腺病理疾患の治療剤
US5534426A (en) * 1993-07-19 1996-07-09 The Regents Of The University Of California Oncoprotein protein kinase
US6514745B1 (en) * 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
WO1995022331A1 (en) * 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
DE69715862T2 (de) 1996-06-25 2003-04-10 Cephalon, Inc. Verwendung eines k-252a derivats zur behandlung von periphärer oder zentraler nervenerkrankungen und übermässiger cytokinbildung
CN1285836A (zh) 1997-12-31 2001-02-28 赛福伦公司 3′－差向异构的K－252a衍生物
ATE212552T1 (de) 1998-04-17 2002-02-15 Tufts College Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
GB9811624D0 (en) 1998-05-29 1998-07-29 Merck Sharp & Dohme Therapeutic use
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
ATE293254T1 (de) 1998-08-26 2005-04-15 Cephalon Inc Modulierung von mlk- (multiple lineage kinase) proteinen
CA2354510A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles
WO2000035921A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4,5-pyrazinoxindoles as protein kinase inhibitors
AU760039B2 (en) 1998-12-17 2003-05-08 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of JNK protein kinases
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
AU4483000A (en) 1999-04-23 2000-11-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
WO2000075118A1 (en) 1999-06-03 2000-12-14 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)
WO2001001986A1 (en) 1999-07-02 2001-01-11 Lipton Stuart A Method of reducing neuronal injury or apoptosis
AU6068600A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
BR0013551A (pt) 1999-08-13 2003-06-17 Vertex Pharma Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
CN1304375C (zh) 1999-08-19 2007-03-14 信号药品公司 用作jnk抑制剂的吡唑并蒽酮及其衍生物和它们的组合物
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
CA2410475A1 (en) 2000-06-01 2001-12-06 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
WO2002038035A2 (en) 2000-11-08 2002-05-16 The General Hospital Corporation Methods for inhibiting pain
EP1343781B1 (de) 2000-12-05 2008-09-03 Vertex Pharmaceuticals Incorporated Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen

Also Published As

Publication number Publication date
MXPA03010451A (es) 2004-05-05
CA2447091A1 (en) 2002-11-21
CA2447091C (en) 2012-03-27
US7018999B2 (en) 2006-03-28
DE60229233D1 (de) 2008-11-20
DK1389100T3 (da) 2008-12-08
US20030087899A1 (en) 2003-05-08
HK1062806A1 (en) 2004-11-26
EP1389100A2 (de) 2004-02-18
EP1389100B1 (de) 2008-10-08
JP2004534751A (ja) 2004-11-18
WO2002092065A2 (en) 2002-11-21
ES2314101T3 (es) 2009-03-16
WO2002092065A3 (en) 2003-07-31
AR035971A1 (es) 2004-07-28
ATE410201T1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
AU2002310187A1 (en) Inhibitors of protein kinase for the treatment of disease
AU2002351397A1 (en) Systems and methods using vasoconstriction for improved thermal treatment of tissues
HK1079426A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
EP1511730B8 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
AU2002257936A1 (en) Methods of well treatment
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
WO2003033720A8 (en) Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
GB0121155D0 (en) Treatment of substrates
AU2003268424A1 (en) Treatment of pain by inhibition of p38 map kinase
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
WO2002076396A3 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
AU2003210983A1 (en) Kinase inhibitors and methods of use thereof
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
GB0124124D0 (en) Methods of treatment
AU2002257114A1 (en) Treatment of malaria with farsenyl protein transferase inhibitors
AU2002342715A1 (en) Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors
AU2566201A (en) Compounds and methods for the treatment of pain
GB2410744B (en) Kinase inhibitors for the treatment of disease
AUPR731901A0 (en) Method of treatment
AU2002306845A1 (en) Telomerase inhibitors and methods of their use
GB0100092D0 (en) Treatment of degenerative diseases
AU2420201A (en) Compounds and methods for the treatment of pain
AU2003294697A1 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain
AU2003293714A1 (en) Methods for the treatment of chronic pain and compositions therefor

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase